ZURICH, Feb 27 (Reuters) - Roche extended its $5.7 billion hostile cash bid for U.S. gene decoder Illumina on Monday, showing the Swiss drugmaker's willingness to play a waiting game, an M&A strategy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback